Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.

Literature DB >> 28589418

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.

T Lehmann¹, D Aeberli².

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2017 PMID： 28589418 DOI： 10.1007/s00198-017-4108-y

Source DB: PubMed Journal: Osteoporos Int ISSN： 0937-941X Impact factor: 4.507

× No keyword cloud information.

4 in total

1. Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD.

Authors: John A Shepherd; John T Schousboe; Susan B Broy; Klaus Engelke; William D Leslie
Journal: J Clin Densitom Date: 2015 Jul-Sep Impact factor: 2.617

2. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?

Authors: Douglas C Bauer
Journal: J Bone Miner Res Date: 2011-02 Impact factor: 6.741

3. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.

Authors: Olivier Lamy; Elena Gonzalez-Rodriguez; Delphine Stoll; Didier Hans; Bérengère Aubry-Rozier
Journal: J Clin Endocrinol Metab Date: 2017-02-01 Impact factor: 5.958

4. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.

Authors: A W Popp; P K Zysset; K Lippuner
Journal: Osteoporos Int Date: 2015-12-22 Impact factor: 4.507

4 in total

7 in total

Review 1. Stopping Denosumab.

Authors: Olivier Lamy; Delphine Stoll; Bérengère Aubry-Rozier; Elena Gonzalez Rodriguez
Journal: Curr Osteoporos Rep Date: 2019-02 Impact factor: 5.096

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.

1. Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT: Fracture Prediction Beyond BMD.

2. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?

3. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.

4. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.

Review 1. Stopping Denosumab.

2. Effect of risedronate on bone loss at discontinuation of denosumab.

3. Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year.

Review 4. Should denosumab treatment for osteoporosis be continued indefinitely?

5. Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab.

6. The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.

Review 7. Management of glucocorticoid-related osteoporotic vertebral fracture.